A detailed history of Creative Planning transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Creative Planning holds 36,214 shares of PTGX stock, worth $3.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,214
Previous 30,204 19.9%
Holding current value
$3.06 Million
Previous $1.67 Million 44.1%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$49.7 - $67.42 $298,697 - $405,194
6,010 Added 19.9%
36,214 $2.41 Million
Q2 2025

Aug 08, 2025

BUY
$40.89 - $56.37 $526,295 - $725,538
12,871 Added 74.26%
30,204 $1.67 Million
Q1 2025

May 15, 2025

BUY
$35.09 - $59.76 $381,954 - $650,487
10,885 Added 168.81%
17,333 $838,000
Q4 2024

Feb 14, 2025

SELL
$38.51 - $48.43 $40,666 - $51,142
-1,056 Reduced 14.07%
6,448 $248,000
Q3 2024

Oct 11, 2024

BUY
$33.72 - $47.33 $253,034 - $355,164
7,504 New
7,504 $337,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $4.15B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.